SuperGen Inc. (Nasdaq:
SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, announced the presentation of data that
describe how its lead JAK2 kinase inhibitors prevent cancer cell
proliferation in non-clinical models (Poster 779, Abstract 3560). This data
is part of a series of presentations at the American Society of
Hematology's 49th Annual Meeting taking place at the Georgia World Congress
Center in Atlanta.
Entitled "Targeting the JAK2 in Hematological Malignancies," the poster
described how SuperGen used its CLIMB(TM) technology to build several
models that were utilized for screening 2.3 million virtual small molecule
compounds. This process generated a subset of leads that were screened
using in silico algorithms to identify "druggable" candidates to pursue.
Testing of the lead candidates in treated leukemia cell cultures indicated
that the JAK2 kinase inhibitors were active against both wild-type and
mutant JAK2 kinase activity and caused potent inhibition of cancer cell
proliferation.
"Our JAK2 kinase inhibitor program is a good example of how we deploy
our CLIMB(TM) drug discovery process to identify and optimize pre-clinical
drug candidates," said Dr. Gregory Berk, SuperGen's Chief Medical Officer.
"This proprietary process allows us to rapidly enter pre-clinical testing
with drug candidates. The in vitro inhibition of cancer cell proliferation
by our lead JAK2 kinase inhibitors demonstrates the promise that this
program holds to treat both hematological cancers and solid tumors."
A copy of the poster presentation will be available in the pipeline
section of SuperGen's Web site supergen.
About SuperGen
Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company
dedicated to the discovery, rapid development and commercialization of
therapies for solid tumors and hematological malignancies. SuperGen is
developing a number of therapeutic anticancer products focused on kinase
and cell signaling inhibitors and DNA methyltransferase inhibitors. For
more information about SuperGen, please visit supergen.
Forward-Looking Statements
This news release contains certain "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "expects,"
"anticipates," "intends," "will," "may," "should," or similar expressions.
These forward-looking statements are not guarantees of future performance
and involve a number of risks and uncertainties that may cause actual
results to differ materially from the results discussed in these
statements. Factors that might cause the company's results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, the ability to discover,
develop and move target compounds into clinical development and other risks
and uncertainties detailed from time to time in the company's filings with
the Securities and Exchange Commission including its most recently filed
Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of
these forward-looking statements to conform them to actual results.
SuperGen Inc.
supergen